new glp 1 agonist novo nordisk GLP-1 Drug Meets Goals of MASH Trial, Setting Stage for FDA & EMA Filings Novo Nordisk stops trial of
Description
According to the latest Global Diabetes Map (10th edition) released by the International Diabetes Federation (IDF) in December 2021, the number of people aged 20 to 79 with diabetes worldwide was estimated at 537 million in 2021, with the number expected to grow to 700 million by 2045
New indications expand use cases Perhaps just as important as the wave of new GLP-1/GIP drugs for obesity is the expansion of already approved GLP-1 drugs into other therapeutic areas
Saxenda contains the active drug liraglutide, which is a protein-based drug
The injectable medication is designed for long-term use, with Zepbound intended for ongoing treatment alongside a reduced-calorie diet and increased physical activity including aerobic exercise
For example, they may have read or heard about a newer treatment or may have a preference for one delivery device or route over another
